MindMed announces it will host a webinar on substance abuse disorders and withdrawal management that includes prominent experts in this field.

A plethora of drug R&D opportunities. A multitude of badly under-served healthcare treatment markets. A medical “miracle”; an investment pot of gold.

Optimi Health announces the completion of its previously announced lab expansion for its Princeton, British Columbia facility.

Enveric Bioscience announces it is spinning off its cannabinoid R&D pipeline into a stand-alone entity.

Mind Medicine Inc announces strong clinical results from its Phase 2 clinical trial using MM-120 for the treatment of Generalized Anxiety Disorder (GAD).

Compass Pathways announces the first-ever study of psilocybin therapy on autistic adults, using COMP360.

Compass Pathways reports its Q1 for 2022. Net loss of $21.2 million on increased R&D expenses. Cash position of $243.7 million.

Red Light Holland submits a new patent application for its microdosing kits.

Cybin announces more early success with with its Kernel Flow(R) technology to measure the neurological effects of ketamine therapy.

Pharmather announces receiving a patent from the USPTO for its “ketamine flow synthesis”. Pharmather has exclusive worldwide development and commercial rights to this IP.